A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis

Journal:

Kidney International

Published:

2026-05-21

DOI:

10.1016/j.kint.2026.03.030

Affiliations:

9

Authors:

9

Go to article

Institutions	Authors	Share
GSK, United Kingdom (UK)	2.000000	0.22
GlaxoSmithKline USA, United States of America (USA)	2.000000	0.22
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, United States of America (USA)	1.000000	0.11
University Hospital of Munich (KUM), LMU, Germany	1.000000	0.11
University of Crete (UOC), Greece	1.000000	0.11
GlaxoSmithKline Ireland, Ireland	1.000000	0.11
Ohio State University Wexner Medical Center (OSUWMC), United States of America (USA)	1.000000	0.11

Interested in Clinical Sciences?